Clinical trials: Atherosclerotic Lesion(s)
Coronary Stenosis
Thin Strut Sirolimus-eluting Stent in All Comers Population vs Everolimus-eluting Stent
The primary objective of this study is to compare the performance of SUPRAFLEX to that of XIENCE in an all-comers patient population with symptomatic ischemic heart disease.
- Trial name
- TALENT (NCT02870140)
- Testing
- SUPRAFLEX, XIENCE
- Where
- 23 sites in Bulgaria, Hungary and 5 more
- Volunteers
- 1,435 people
- Sponsor
- ECRI bv
Coronary Artery Disease
Safety and Effectiveness of the Orsiro Mission 48-mm Sirolimus Eluting Coronary Stent System in Subjects With Coronary Artery Lesions
The purpose of the study is to assess the safety and efficacy of the Orsiro® Mission 48- mm Sirolimus-Eluting Coronary Stent System in the treatment of subjects with atherosclerotic lesion(s) >36 mm and ≤ 44 mm in length (by…
- Trial name
- BIOFLOW-48 (NCT06779630)
- Testing
- Orsiro Mission 48-mm Sirolimus-Eluting Coronary Stent System
- Where
- 23 sites in United States, Austria and 4 more
- Volunteers
- 150 people
- Sponsor
- Teleflex
Atherosclerosis
PE PREMIER CHINA CLINICAL TRIAL
PE PREMIER China: A Prospective, Multicenter Trial to Assess the Promus PREMIERTM Everolimus-Eluting Platinum Chromium Coronary Stent System for the Treatment of Atherosclerotic Lesion(s)
- Trial name
- NCT02230254
- Testing
- Percutaneous coronary intervention PROMUS PREMIER
- Volunteers
- 101 people
- Sponsor
- Boston Scientific Corporation
Atherosclerotic Lesion(s)
EVOLVE II QCA: A Prospective, Multicenter Trial to Assess the SYNERGY Stent System for the Treatment of Atherosclerotic Lesion(s)
The purpose of this study is to evaluate 9 month angiographic and intravascular ultrasound (IVUS) data for the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System (SYNERGY Stent System) in the treatment of subjects…
- Trial name
- EVOLVE II QCA (NCT01787799)
- Testing
- SYNERGY
- Where
- 13 sites in Australia, Japan and 2 more
- Volunteers
- 100 people
- Sponsor
- Boston Scientific Corporation
Coronary Artery Disease
The EVOLVE China Clinical Trial
The purpose of this study is to assess the safety and effectiveness of the SYNERGY™ Coronary Stent System for the treatment of subjects with atherosclerotic lesion(s) ≤ 34 mm in length (by visual estimate) in native coronary…
- Trial name
- EVOLVE-CHINA (NCT01966159)
- Testing
- SYNERGY Investigational Device, PE Plus Investigational Device
- Where
- 14 sites in China
- Volunteers
- 412 people
- Sponsor
- Boston Scientific Corporation
Coronary Artery Disease
A Clinical Trial to Assess the SYNERGY 48 mm Stent System for the Treatment of Atherosclerotic Lesion(s)
EVOLVE 48 is a prospective, open label, single arm, multi-center trial. The purpose of this study is to assess the FDA requirement for safety and effectiveness of the SYNERGY 48 mm Coronary Stent System for the treatment of…
- Trial name
- EVOLVE48 (NCT03350542)
- Testing
- SYNERGY 48 mm
- Where
- 15 sites in United States, Latvia and 2 more
- Volunteers
- 100 people
- Sponsor
- Boston Scientific Corporation
Renal Stenting in the Treatment of Pts w/a High Grade Ostial Atherosclerotic Renal Lesion(s).
Safety & Performance Study of Lumen Biomedical's FiberNet Distal Protection System for the Treatment of Renal Artery Stenosis
To evaluate the procedural safety and filter efficiency of the FiberNet® Embolic Protection System when used in conjunction with the Boston Scientific Express SD Stent System for primary stenting of ostial atherosclerotic renal…
- Trial name
- FORTRESS (NCT00674505)
- Testing
- Lumen Biomedical FiberNet Embolic Protection System
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- VIVA Physicians
Cardiovascular Diseases
SYNERGY China: Assess SYNERGY Stent in China
Prospective, multicenter, single-arm study, enroll 100 patients in no more than 10 sites across China, the primary endpoint is Technical success.
- Trial name
- NCT02499692
- Testing
- SYNERGYTM Coronary Stent System
- Where
- 8 sites in China
- Volunteers
- 103 people
- Sponsor
- Boston Scientific Corporation
Atherosclerosis, Coronary Artery Disease
NG PROMUS Stent System for the Treatment of Atherosclerotic Coronary Lesions
NG PROMUS: A Prospective, Multicenter Trial to Assess the NG PROMUS Everolimus-Eluting Platinum Chromium Coronary Stent System (NG PROMUS Stent System) for the Treatment of Atherosclerotic Lesion(s)
- Trial name
- NCT01703000
- Testing
- Percutaneous coronary intervention (NG PROMUS)
- Where
- 9 sites in Australia, New Zealand and 1 more
- Volunteers
- 100 people
- Sponsor
- Boston Scientific Corporation
Atherosclerosis, Heart Diseases, Coronary
A Clinical Trial to Confirm Safety & Effectiveness of the SYNERGY 4.50 mm and 5.00 mm Stent for Treatment of Atherosclerotic Lesion(s)
EVOLVE 4.5/5.0 is a prospective, single-arm, multi-center observational (standard of care) trial intended to confirm the safety and effectiveness of the SYNERGY 4.50 mm and 5.00 mm Coronary Stent System for the treatment of…
- Conditions
- Atherosclerosis, Heart Diseases, Coronary, Coronary Artery Disease, Cardiovascular Diseases
- Trial name
- NCT03875651
- Testing
- SYNERGY 4.50 mm and 5.0 mm Coronary Stent System
- Where
- 9 sites in United States
- Volunteers
- 100 people
- Sponsor
- Boston Scientific Corporation
Coronary Artery Disease
The EVOLVE II Clinical Trial To Assess the SYNERGY Stent System for the Treatment of Atherosclerotic Lesion(s)
The purpose of this study is to assess the safety and effectiveness of the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System for the treatment of subjects with atherosclerotic lesion(s) ≤ 34 mm in length (by…
- Trial name
- NCT01665053
- Testing
- PROMUS Element Plus, SYNERGY
- Where
- 126 sites in United States, Australia and 14 more
- Volunteers
- 1,684 people
- Sponsor
- Boston Scientific Corporation
Coronary Artery Disease
Non-inferiority Study Comparing Firehawk Stent With Abbott Xience Family Stent (TARGET-AC)
Purpose The TARGET All comers trial is a prospective, multicenter, randomized, two-arm, non-inferiority, open-label study with 1656 patients at 20 centers in Europe. The study is a "real world, all comers" study.
- Trial name
- NCT02520180
- Testing
- Firehawk™ stent system, Abbott Xience family Everolimus-Eluting Stent
- Where
- Denmark
- Volunteers
- 1,653 people
- Sponsor
- Shanghai MicroPort Medical (Group) Co., Ltd.